Sign In
Buy STRO
$25.53
+0.150 (+0.591%)
At Close: Aug 10, 2026
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
04:30pm, Thursday, 03'rd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre
